University of Helsinki
Prof. Yliperttula leads the multidisciplinary and multinational Biopharmaceutics research group at the University of Helsinki’s Faculty of Pharmacy.
The research program consists of the development of biomaterials for cell culture, drug delivery, and tissue repair together with detection technology. The developed biomaterials are based on nanofibrillated cellulose, nanoparticles, and extracellular vesicles.
Two of the most important projects on-going in the Biopharmacy research group are:
- EV Ecosystem: https://www.bloodservice.fi/Research%20Projects/ev-ecosystem
- GeneCellNano Flagship: https://www.genecellnano.fi
Nanofibrillated cellulose in skin graft donor site treatment (FibDex)
A.Detachment of dressing from donor site. without breaking the newly formed skin.
B.The epithelialised skin without scar formation.
In vitro and in vivo enhanced antitumor effects of oncolytic virus and paclitaxel encapsulated in extracellular vesicles (EVs).
A.Lung cancer cells were implanted subcutaneously into mice and EV formulations were administered intravenously (i.v.). Tumor growth was followed over time.
B.Kaplan-Meier test was used to calculate the survival profile.
Funding sources: BioCenter Finland, Tekes-The Finnish Funding Agency for Technology and Innovation, EU-FP7 (LIV-ES project, HEALTH-F5-2008-223317), Graduate School of Pharmaceutical Sciences, Finnish Red Cross Service, MATRENA graduate schools, Academy of Finland and EU-Erasmus Exchange Student Exchange Programme, UPM-GrowDexI I –III projects, UPM-Wound project, Huttunen foundation, professor-pool Orion foundation